Advertisement

Topics

ITM’s Successful Hosting of the Investigator Meeting for Phase III Clinical Trial COMPETE with n.c.a.177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET

09:05 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
ITM’s subsidiary ITM Solucin lead 2-day-event focused on study update and efficient trial execution Meeting attended by over 60 investigators as well as study nurses from 30 leading cancer centers in 10 countries ...

Other Sources for this Article

Media Contact: WE Communications
Stephan Winzler
Account Manager
Phone: +4989 628175-16
Mail: ITM_AG@we-worldwide.com
or
ITM Isotopen Technologien München AG
Nicola Scharrer
Head of Marketing
Phone: +49 89 3298986-16
Mail: Nicola.Scharrer@itm.ag

NEXT ARTICLE

More From BioPortfolio on "ITM’s Successful Hosting of the Investigator Meeting for Phase III Clinical Trial COMPETE with n.c.a.177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...